WO2014009833A3 - Complement pathway modulators and uses thereof - Google Patents
Complement pathway modulators and uses thereof Download PDFInfo
- Publication number
- WO2014009833A3 WO2014009833A3 PCT/IB2013/055302 IB2013055302W WO2014009833A3 WO 2014009833 A3 WO2014009833 A3 WO 2014009833A3 IB 2013055302 W IB2013055302 W IB 2013055302W WO 2014009833 A3 WO2014009833 A3 WO 2014009833A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- complement pathway
- pathway modulators
- present
- provides
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201590200A EA201590200A1 (en) | 2012-07-12 | 2013-06-27 | MODULATORS OF THE COMPLEMENT ACTIVATION WAY AND THEIR APPLICATION |
EP13765778.9A EP2872503B1 (en) | 2012-07-12 | 2013-06-27 | Complement pathway modulators and uses thereof |
US14/409,914 US9550755B2 (en) | 2012-07-12 | 2013-06-27 | Complement pathway modulators and uses thereof |
KR20157003423A KR20150036481A (en) | 2012-07-12 | 2013-06-27 | Complement pathway modulators and uses thereof |
AU2013288319A AU2013288319A1 (en) | 2012-07-12 | 2013-06-27 | Complement pathway modulators and uses thereof |
BR112015000578A BR112015000578A2 (en) | 2012-07-12 | 2013-06-27 | complement pathway modulators and their uses |
MX2015000537A MX2015000537A (en) | 2012-07-12 | 2013-06-27 | Complement pathway modulators and uses thereof. |
IN185DEN2015 IN2015DN00185A (en) | 2012-07-12 | 2013-06-27 | |
CA2882724A CA2882724A1 (en) | 2012-07-12 | 2013-06-27 | Complement pathway modulators and uses thereof |
CN201380046562.3A CN104684910B (en) | 2012-07-12 | 2013-06-27 | Complement is by way of regulator and application thereof |
ES13765778.9T ES2687983T3 (en) | 2012-07-12 | 2013-06-27 | Modulators of the complement path and uses thereof |
JP2015521093A JP6238980B2 (en) | 2012-07-12 | 2013-06-27 | Complement pathway modulators and uses thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261670868P | 2012-07-12 | 2012-07-12 | |
US61/670,868 | 2012-07-12 | ||
US201361774234P | 2013-03-07 | 2013-03-07 | |
US61/774,234 | 2013-03-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014009833A2 WO2014009833A2 (en) | 2014-01-16 |
WO2014009833A3 true WO2014009833A3 (en) | 2014-03-20 |
Family
ID=49226214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2013/055302 WO2014009833A2 (en) | 2012-07-12 | 2013-06-27 | Complement pathway modulators and uses thereof |
Country Status (13)
Country | Link |
---|---|
US (1) | US9550755B2 (en) |
EP (1) | EP2872503B1 (en) |
JP (1) | JP6238980B2 (en) |
KR (1) | KR20150036481A (en) |
CN (1) | CN104684910B (en) |
AU (1) | AU2013288319A1 (en) |
BR (1) | BR112015000578A2 (en) |
CA (1) | CA2882724A1 (en) |
EA (1) | EA201590200A1 (en) |
ES (1) | ES2687983T3 (en) |
IN (1) | IN2015DN00185A (en) |
MX (1) | MX2015000537A (en) |
WO (1) | WO2014009833A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2940777A1 (en) * | 2014-02-25 | 2015-09-03 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of complement mediated disorders |
AR105809A1 (en) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
AR105808A1 (en) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | AMIDA COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
EP3340982B1 (en) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
AR106018A1 (en) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
US10000516B2 (en) | 2015-08-26 | 2018-06-19 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
WO2017035355A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
WO2017035401A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
WO2017035351A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
WO2017035405A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
TW202222786A (en) | 2016-02-01 | 2022-06-16 | 美商百歐克斯製藥公司 | Benzopyrazole compounds and analogues thereof |
AU2017290593A1 (en) | 2016-06-27 | 2019-01-03 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
EP3589628A4 (en) | 2017-03-01 | 2021-03-31 | Achillion Pharmaceuticals, Inc. | Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
ES2933513T3 (en) | 2017-03-01 | 2023-02-09 | Achillion Pharmaceuticals Inc | Macrocyclic compounds for the treatment of medical disorders |
WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
JP2021535112A (en) | 2018-08-20 | 2021-12-16 | アキリオン ファーマシューティカルズ,インコーポレーテッド | Pharmaceutical compounds for the treatment of medical disorders of complement D factor |
BR112021004263A2 (en) | 2018-09-06 | 2021-05-25 | Achillion Pharmaceuticals, Inc. | morphic forms of danicopane |
EP3846803A4 (en) | 2018-09-06 | 2022-08-10 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
MX2021003425A (en) | 2018-09-25 | 2021-07-16 | Achillion Pharmaceuticals Inc | Morphic forms of complement factor d inhibitors. |
EP4149473A1 (en) | 2020-05-12 | 2023-03-22 | Alexion Pharmaceuticals, Inc. | Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006039252A2 (en) * | 2004-10-01 | 2006-04-13 | Merck & Co., Inc. | Compositions and methods for treating ophthalmic diseases |
WO2010066684A2 (en) * | 2008-12-09 | 2010-06-17 | Novartis Ag | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease |
US20120004245A1 (en) * | 2010-07-02 | 2012-01-05 | Alcon Research, Ltd. | Compounds for the treatment of posterior segment disorders and diseases |
WO2012093101A1 (en) * | 2011-01-04 | 2012-07-12 | Novartis Ag | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd) |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
US5164372A (en) | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
DE59309867D1 (en) | 1992-09-03 | 1999-12-16 | Boehringer Ingelheim Pharma | NEW AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS |
US5661161A (en) | 1994-09-29 | 1997-08-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5756528A (en) | 1995-06-06 | 1998-05-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CN1299346A (en) | 1998-06-03 | 2001-06-13 | Gpi;Nil控股公司 | Ureas and carbamates of N-heterocyclic carboxylic acids and carboxylic acid isosteres |
CA2333679A1 (en) | 1998-06-03 | 1999-12-09 | Gpi Nil Holdings, Inc. | Small molecule carbamate or urea hair growth compositions and uses |
AU770459B2 (en) | 1998-06-03 | 2004-02-19 | Gpi Nil Holdings, Inc. | Heterocyclic ester and amide hair growth compositions and uses |
US7338976B1 (en) | 1998-08-14 | 2008-03-04 | Gpi Nil Holdings, Inc. | Heterocyclic esters or amides for vision and memory disorders |
CA2321348A1 (en) | 2000-09-27 | 2002-03-27 | Blaise Magloire N'zemba | Aromatic derivatives with hiv integrase inhibitory properties |
CA2426271A1 (en) | 2000-10-19 | 2002-04-25 | Naeja Pharmaceutical Inc. | Dihydropyrimidine derivatives as cysteine protease inhibitors |
US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
TWI317634B (en) | 2001-12-13 | 2009-12-01 | Nat Health Research Institutes | Aroyl indoles compounds |
NL1021590C1 (en) | 2002-10-05 | 2004-04-06 | Johannes Antonius Josep Visser | Harvesting device for harvesting crops and sorting device. |
CA2505127A1 (en) | 2002-11-08 | 2004-05-27 | James B. Doherty | Ophthalmic compositions for treating ocular hypertension |
US7632858B2 (en) | 2002-11-15 | 2009-12-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
CN102267924A (en) | 2003-01-08 | 2011-12-07 | 诺华疫苗和诊断公司 | Antibacterial agents |
WO2004062607A2 (en) | 2003-01-13 | 2004-07-29 | Ying Zhang | Use of weak acids or their precursors for the treatment of tuberculosis (tb) and drug resistant tb |
US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
JP2007524596A (en) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | Co-crystal pharmaceutical composition |
US7122557B2 (en) | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
KR20050118708A (en) | 2003-04-03 | 2005-12-19 | 메르크 파텐트 게엠베하 | Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases |
US7959919B2 (en) | 2003-11-19 | 2011-06-14 | Novelmed Therapeutics, Inc. | Method of inhibiting factor B-mediated complement activation |
EP2340850A1 (en) | 2004-02-10 | 2011-07-06 | The Regents of the University of Colorado, a Body Corporate | Inhibition of factor B, the alternative complement pathway and methods related thereto |
US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
DE102004045796A1 (en) | 2004-09-22 | 2006-03-23 | Merck Patent Gmbh | Medicaments containing carbonyl compounds and their use |
FR2876692B1 (en) | 2004-10-19 | 2007-02-23 | Sanofi Aventis Sa | 2-AMIDO-4-PHENYLTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
DE602005015033D1 (en) | 2005-02-28 | 2009-07-30 | Tseti Ioulia | MEDICAMENTS AGAINST ALZHEIMER DISEASE |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
AU2006251590A1 (en) | 2005-05-23 | 2006-11-30 | Merck & Co., Inc. | Proline bis-amide orexin receptor antagonists |
NZ565540A (en) | 2005-08-02 | 2011-06-30 | Vertex Pharma | Inhibitors of serine proteases |
CN105582523B (en) | 2005-10-08 | 2022-04-15 | 阿佩利斯制药公司 | Compstatin and analogs thereof for ocular disorders |
KR20080080170A (en) | 2005-12-12 | 2008-09-02 | 제네랩스 테크놀로지스, 인코포레이티드 | N-(5-membered heteroaromatic ring)-amido anti-viral compounds |
PL2596807T3 (en) | 2006-03-08 | 2016-06-30 | Archemix Llc | Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders |
WO2008036967A2 (en) | 2006-09-22 | 2008-03-27 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds as lasy activators |
CN106084055A (en) | 2006-11-02 | 2016-11-09 | 健泰科生物技术公司 | Humanized anti-D factor antibody |
WO2008064218A2 (en) | 2006-11-21 | 2008-05-29 | Smithkline Beecham Corporation | Amido anti-viral compounds |
EP1988098A1 (en) | 2007-04-27 | 2008-11-05 | AEterna Zentaris GmbH | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors |
AR066660A1 (en) | 2007-05-23 | 2009-09-02 | Genentech Inc | PREVENTION AND TREATMENT OF EYE CONDITIONS ASSOCIATED WITH THEIR COMPLEMENT |
WO2009106980A2 (en) | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Indazole derivatives |
WO2010020675A1 (en) | 2008-08-22 | 2010-02-25 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
US8211928B2 (en) * | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2013
- 2013-06-27 EA EA201590200A patent/EA201590200A1/en unknown
- 2013-06-27 CA CA2882724A patent/CA2882724A1/en not_active Abandoned
- 2013-06-27 MX MX2015000537A patent/MX2015000537A/en unknown
- 2013-06-27 WO PCT/IB2013/055302 patent/WO2014009833A2/en active Application Filing
- 2013-06-27 EP EP13765778.9A patent/EP2872503B1/en active Active
- 2013-06-27 BR BR112015000578A patent/BR112015000578A2/en not_active IP Right Cessation
- 2013-06-27 US US14/409,914 patent/US9550755B2/en active Active
- 2013-06-27 JP JP2015521093A patent/JP6238980B2/en active Active
- 2013-06-27 AU AU2013288319A patent/AU2013288319A1/en not_active Abandoned
- 2013-06-27 CN CN201380046562.3A patent/CN104684910B/en active Active
- 2013-06-27 ES ES13765778.9T patent/ES2687983T3/en active Active
- 2013-06-27 IN IN185DEN2015 patent/IN2015DN00185A/en unknown
- 2013-06-27 KR KR20157003423A patent/KR20150036481A/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006039252A2 (en) * | 2004-10-01 | 2006-04-13 | Merck & Co., Inc. | Compositions and methods for treating ophthalmic diseases |
WO2010066684A2 (en) * | 2008-12-09 | 2010-06-17 | Novartis Ag | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease |
US20120004245A1 (en) * | 2010-07-02 | 2012-01-05 | Alcon Research, Ltd. | Compounds for the treatment of posterior segment disorders and diseases |
WO2012093101A1 (en) * | 2011-01-04 | 2012-07-12 | Novartis Ag | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd) |
Also Published As
Publication number | Publication date |
---|---|
KR20150036481A (en) | 2015-04-07 |
CN104684910A (en) | 2015-06-03 |
CN104684910B (en) | 2016-10-12 |
CA2882724A1 (en) | 2014-01-16 |
BR112015000578A2 (en) | 2017-06-27 |
ES2687983T3 (en) | 2018-10-30 |
EA201590200A1 (en) | 2015-08-31 |
IN2015DN00185A (en) | 2015-06-12 |
EP2872503B1 (en) | 2018-06-20 |
US9550755B2 (en) | 2017-01-24 |
EP2872503A2 (en) | 2015-05-20 |
MX2015000537A (en) | 2015-05-11 |
WO2014009833A2 (en) | 2014-01-16 |
JP2015522062A (en) | 2015-08-03 |
AU2013288319A1 (en) | 2015-02-05 |
JP6238980B2 (en) | 2017-11-29 |
US20150148374A1 (en) | 2015-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014002051A3 (en) | Complement pathway modulators and uses thereof | |
WO2014002058A3 (en) | Complement pathway modulators and uses thereof | |
WO2014009833A3 (en) | Complement pathway modulators and uses thereof | |
PH12014502462A1 (en) | Complement pathway modulators and uses thereof | |
TN2014000030A1 (en) | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators | |
PH12016500072A1 (en) | Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof | |
MX2016000675A (en) | Aminomethyl-biaryl derivatives as complement factor d inhibitors and uses thereof. | |
MY163083A (en) | Solid forms of a pharmaceutically active substance | |
EA201590118A1 (en) | PYRROLIDINE DERIVATIVES AND THEIR APPLICATION AS MODULATORS OF THE COMPLEMENT ACTIVATION | |
AU2014338549A8 (en) | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | |
TN2013000275A1 (en) | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd) | |
SG194463A1 (en) | Glycoside derivatives and their uses for the treatment of diabetes | |
MX2020007023A (en) | Thiadiazole analogs thereof and methods for treating smn-deficiency-related-conditions. | |
MY168212A (en) | A new therapeutical composition containing apomorphine as active ingredient | |
WO2012140596A8 (en) | Glycoside derivatives and uses thereof | |
PH12015501386A1 (en) | Tricyclic compounds | |
TN2014000060A1 (en) | Benzothiazolone compound | |
MX2016006667A (en) | Pyrrolopyrrolone derivatives and their use as bet inhibitors. | |
TN2012000617A1 (en) | 2,3,5-trisubstituted thiophene compounds and uses thereof | |
TN2015000058A1 (en) | Salts of benzothiazolone compound as beta-2-adrenoceptor agonist | |
WO2013035997A3 (en) | Pharmaceutical composition for preventing or treating alopecia comprising tianeptine or its salt | |
CO7141426A2 (en) | Modulators of the complement path and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13765778 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14409914 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2882724 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015521093 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/000537 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013765778 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013288319 Country of ref document: AU Date of ref document: 20130627 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20157003423 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201590200 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015000578 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015000578 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150109 |